ArticleBioinformation2025
Analytical cohort study on splenomegaly and cytopenias in myeloproliferative disorders.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationship between splenomegaly and cytopenias in myeloproliferative disorders (MPDs) remains poorly defined despite its clinical importance. This analytical cohort study evaluated 124 patients with MPDs, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, to characterize associations between splenic enlargement and hematologic abnormalities. Splenomegaly was present in 68.5% of patients and showed significant correlations with anemia and thrombocytopenia. Individuals with massive splenomegaly demonstrated greater symptom burden and more pronounced pancytopenia. These findings suggest that splenic size may serve as an important indicator of disease severity and may guide early therapeutic decision-making in MPD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.